PUBLISHER: The Business Research Company | PRODUCT CODE: 1730939
PUBLISHER: The Business Research Company | PRODUCT CODE: 1730939
Malignant pleural effusion (MPE) is the buildup of fluid in the pleural space caused by the presence of cancer cells, usually due to metastatic disease. This condition occurs when cancer spreads to the pleura, the thin membrane surrounding the lungs, resulting in increased vascular permeability and impaired lymphatic drainage.
The main treatment options for malignant pleural effusion include systemic therapy, therapeutic thoracentesis, thoracic drainage and pleurodesis, and the placement of an indwelling pleural catheter. Systemic therapy is a cancer treatment that circulates through the bloodstream to target and eliminate cancer cells throughout the body. Diagnosis is typically performed using methods such as pleural fluid cytology, immunohistochemical tests, imaging tests, pleural thoracentesis, pleuroscopy, and pleural biopsy. These treatments and diagnostic procedures are utilized by various end users, including hospitals, ambulatory clinics, and other healthcare facilities.
The malignant pleural effusion market research report is one of a series of new reports from The Business Research Company that provides malignant pleural effusion market statistics, including the malignant pleural effusion industry global market size, regional shares, competitors with the malignant pleural effusion market share, detailed malignant pleural effusion market segments, market trends, and opportunities, and any further data you may need to thrive in the malignant pleural effusion industry. This malignant pleural effusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The malignant pleural effusion market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing adoption of indwelling pleural catheters, a greater focus on palliative care, a rise in clinical trials, higher reimbursement rates, and the growing prevalence of metastatic malignancies.
The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure, increased government support, a rising number of cancer survivors, growing demand for home-based care, and advancements in liquid biopsy. Key trends during this period include the integration of artificial intelligence in imaging tools, progress in targeted cancer therapies, advancements in pleurodesis, improvements in biomarkers, and the expansion of clinical trials for novel therapeutic agents.
The increasing number of lung cancer cases is expected to drive the growth of the malignant pleural effusion market. Lung cancer is a disease marked by the uncontrolled growth of abnormal cells in the lungs, which can form tumors and disrupt normal lung function. The rise in lung cancer cases is largely due to smoking and tobacco use, as long-term exposure to harmful chemicals in cigarettes damages lung tissues, causes genetic mutations, and encourages the uncontrolled growth of cancerous cells, significantly raising the risk of developing the disease. Malignant pleural effusion signals advanced lung cancer progression by aiding the spread of tumors within the pleural cavity, which worsens respiratory function and leads to a poorer prognosis. For example, in January 2023, the American Cancer Society, a U.S.-based professional organization, reported that in 2022, there were an estimated 236,740 new cases of lung and bronchus cancer, with 130,180 estimated deaths. For 2023, new cases are expected to rise to 238,340, with deaths expected to decrease slightly to 127,070. This increase in lung cancer cases is driving the growth of the malignant pleural effusion market.
The improvement of healthcare infrastructure is anticipated to further fuel the growth of the malignant pleural effusion market. Healthcare infrastructure encompasses the physical, technological, and organizational elements required for delivering healthcare services, such as hospitals, clinics, medical equipment, IT systems, and healthcare personnel. The enhancement of healthcare infrastructure is driven by the need for better disease management and aims to improve accessibility, efficiency, and care quality. It supports better diagnosis, treatment, and management of malignant pleural effusion by granting access to advanced medical technologies, better-equipped healthcare facilities, and specialized care, ultimately leading to improved patient outcomes. For instance, in May 2023, the American Health Care Association, a U.S.-based nonprofit organization, reported a 0.591% increase in the number of hospitals in the U.S., rising from 6,093 in the previous year to 6,129. This improvement in healthcare infrastructure is contributing to the growth of the malignant pleural effusion market.
Companies in the malignant pleural effusion market are focusing on developing innovative therapies such as enzyme-targeting therapy to improve treatment outcomes by targeting specific enzymes involved in fluid accumulation. Enzyme-targeting therapy is a medical approach that designs drugs or treatments to specifically inhibit or modify the activity of enzymes associated with diseases. This therapy is commonly applied to conditions such as cancer, metabolic disorders, and infectious diseases, where abnormal enzyme activity contributes to disease progression. For example, in September 2022, RS Oncology, LLC, a U.S.-based biotechnology company, initiated the MITOPE clinical trial, a first-in-human Phase 1/2 study conducted in the United Kingdom. This trial is evaluating RSO-021, a novel PRX3 inhibitor designed to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to eliminate cancer cells while preserving healthy tissue.
Major players in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH.
North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in malignant pleural effusion report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the malignant pleural effusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The malignant pleural effusion market consists of revenues earned by entities by providing services such as biopsy and cytology testing, chemotherapy and targeted therapy, and pleurodesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant pleural effusion market also includes sales of chest drainage systems, pleural access kits, and imaging-guided drainage equipment, and thoracentesis devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Malignant Pleural Effusion Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on malignant pleural effusion market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for malignant pleural effusion ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malignant pleural effusion market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.